MONDAY, JUNE 18, 2018

Menon Biosensors demonstrates industry-leading virus detection

Menon Biosensors, Inc., announced on Thursday that its Molecular Mirroring nuclear magnetic resonance technology detected Mycobacterium tuberculosis and Clostridium difficile successfully in more than 500 samples.

The viruses were detected in concentrations as low as 1 colony-forming unit per sample, and without false positives or negatives.

"With our unique platform detection technology, our scientists were able to develop and optimize our assays for these serious worldwide diseases in just 60 to 90 days, while still delivering unmatched sensitivity," Suresh Menon, the president of Menon Biosensors, said. "In these studies the time from sample to result continues to be less than one hour. We plan to continue to demonstrate the speed and sensitivity of our technology in detecting additional pathogens for individual and public health, including food safety and livestock applications, where timely detection and intervention are very important."

The study was conducted at Scripps Memorial Hospital under the supervision of Pathologist John Spinosa.

The presence of TB and C. difficile was found in water, sputum and stool. Tests were completed in less than one hour, including sample preparation.

Menon Biosensors expects to further develop the test to detect pathogens in lower concentrations. Results from the study will be presented on Jan. 14 at the Biotech Showcase in San Francisco.